Myriad Genetics, Inc. (MYGN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Myriad Genetics, Inc. (MYGN) Healthcare & Pipeline Overview

Myriad Genetics, Inc. specializes in genetic testing and precision medicine, providing molecular diagnostic tests for oncology, women's health, and mental health. With a focus on hereditary cancer risk assessment and personalized treatment strategies, Myriad operates in the competitive diagnostics market, leveraging strategic collaborations to expand its testing services.

What Is the Investment Thesis for MYGN?

Myriad Genetics operates in the growing precision medicine market, with a focus on genetic testing for cancer, women's health, and mental health. The company's gross margin of 70.0% indicates strong pricing power and efficient operations. Key growth catalysts include expanding adoption of its MyRisk Hereditary Cancer Test and BRACAnalysis CDx. The company's strategic collaborations with Illumina and Intermountain Precision Genomics could drive further market penetration. However, a profit margin of -48.2% raises concerns about profitability and cost management. Investors should monitor the company's ability to achieve sustainable profitability and manage its operating expenses effectively.

Based on FMP financials and quantitative analysis

MYGN Key Highlights

Market Cap of $317M reflects its current valuation in the genetic testing market.

• Gross Margin of 70.0% demonstrates strong pricing power and efficient cost management in its testing services.
• Profit Margin of -48.2% indicates ongoing challenges with profitability and expense management.
• Beta of 1.64 suggests higher volatility compared to the broader market.
• Strategic collaborations with Illumina and Intermountain Precision Genomics enhance its market reach and service capabilities.

Who Are MYGN's Competitors?

MYGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MYGN's Key Strengths?

Diverse portfolio of genetic tests.

• Established presence in oncology, women's health, and mental health.
• Strategic collaborations with industry leaders.
• Proprietary technology and intellectual property.

What Are MYGN's Weaknesses?

Negative profit margin.

• High beta indicating higher volatility.
• Dependence on reimbursement policies.
• Competition from larger diagnostic companies.

What Could Drive MYGN Stock Higher?

Expansion of MyRisk Hereditary Cancer Test into new markets.

• Increased adoption of BRACAnalysis CDx in metastatic cancer treatment.
• Growth in mental health testing with GeneSight.
• Strategic collaborations with Illumina and Intermountain Precision Genomics.

What Are the Key Risks for MYGN?

Financial-distress signal — its Altman Z-Score of -1.02 sits in the distress zone (elevated bankruptcy risk).

• Changes in reimbursement policies impacting test pricing.
• Competition from lower-cost providers.
• Patent expirations affecting key products.
• Regulatory hurdles and compliance requirements.

What Are the Growth Opportunities for MYGN?

• Expansion of MyRisk Hereditary Cancer Test: Myriad Genetics can drive growth by expanding the adoption of its MyRisk Hereditary Cancer Test. The hereditary cancer testing market is growing as awareness of genetic predispositions increases. By targeting specific demographics and collaborating with healthcare providers, Myriad can increase test volumes and revenue.
• Increased Adoption of BRACAnalysis CDx: The BRACAnalysis CDx Germline Companion Diagnostic Test offers a significant growth opportunity. As personalized medicine becomes more prevalent, the demand for companion diagnostic tests to guide treatment decisions will increase. By demonstrating the clinical utility and cost-effectiveness of BRACAnalysis CDx, Myriad can drive adoption among oncologists and patients. This test addresses a critical need in the treatment of metastatic cancers, positioning Myriad as a key player in precision oncology.
• Growth in Mental Health Testing with GeneSight: Myriad Genetics can capitalize on the growing demand for mental health testing with its GeneSight Psychotropic Mental Health Medication Test. The market for pharmacogenomic testing in mental health is expanding as healthcare providers seek to optimize treatment outcomes. By demonstrating the value of GeneSight in improving medication selection and reducing adverse effects, Myriad can drive adoption among psychiatrists and primary care physicians. The increasing prevalence of mental health disorders presents a substantial market opportunity.
• Strategic Collaborations for Expanded Services: Myriad Genetics' strategic collaborations with Illumina, Inc. and Intermountain Precision Genomics offer opportunities for expanded services and market reach. By leveraging these partnerships, Myriad can offer a broader range of germline and somatic tumor testing services. These collaborations can also facilitate access to new markets and customer segments. The synergies created through these partnerships can drive revenue growth and enhance Myriad's competitive position.
• Penetration of the Prenatal Screening Market: Myriad Genetics can further penetrate the prenatal screening market with its Prequel Prenatal Screen and Foresight Carrier Screen. The demand for non-invasive prenatal screening is increasing as expectant parents seek to assess the risk of chromosomal disorders and genetic conditions. By offering accurate and reliable prenatal screening tests, Myriad can capture a larger share of this market. The prenatal screening market is expected to continue growing, driven by technological advancements and increasing awareness among parents.

What Are MYGN's Competitive Advantages?

• Proprietary genetic tests with patent protection.
• Established brand reputation in genetic testing.
• Strategic collaborations with key industry players.
• Extensive database of genetic information.
• Specialized expertise in molecular diagnostics.

What Does MYGN Do?

Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics, Inc. has evolved into a leading genetic testing and precision medicine company. The company develops and commercializes a range of molecular diagnostic tests, primarily focusing on oncology, women's health, and mental health. Its offerings include the MyRisk Hereditary Cancer Test, which assesses risks for hereditary cancers through DNA sequencing, and the BRACAnalysis CDx Germline Companion Diagnostic Test, which helps determine therapy for patients with specific metastatic cancers. Myriad also provides the MyChoice CDx Companion Diagnostic Test for ovarian cancer patients. In addition to oncology-focused tests, Myriad offers the Prolaris Prostate Cancer Prognostic Test and the EndoPredict Breast Cancer Prognostic Test, both RNA expression tumor analyses. The company's portfolio extends to prenatal screening with the Prequel Prenatal Screen and the Foresight Carrier Screen. GeneSight Psychotropic Mental Health Medication Test aids in psychotropic drug selection. Myriad Genetics collaborates with Illumina, Inc. and Intermountain Precision Genomics to broaden its germline and somatic tumor testing services, enhancing its market reach and service capabilities.

What Products and Services Does MYGN Offer?

• Develops and commercializes genetic tests.
• Offers molecular diagnostic tests for oncology.
• Provides tests for women's health applications.
• Offers tests for mental health applications.
• Provides hereditary cancer risk assessment through DNA sequencing.
• Offers companion diagnostic tests to guide cancer therapy decisions.
• Provides prenatal screening tests for chromosomal disorders.
• Offers pharmacogenomic testing for mental health medication selection.

How Does MYGN Make Money?

• Develops proprietary genetic tests.
• Commercializes tests through direct sales and partnerships.
• Generates revenue from test orders.
• Collaborates with other companies for research and development.

What Industry Does MYGN Operate In?

Myriad Genetics operates within the medical diagnostics and research industry, which is experiencing growth driven by advancements in genetic sequencing and personalized medicine. The market is competitive, with companies offering a range of diagnostic tests for various diseases. Key trends include the increasing adoption of precision medicine approaches and the growing demand for genetic testing in oncology and prenatal care. Myriad Genetics competes with other diagnostic companies by offering specialized tests and leveraging strategic collaborations to expand its market presence.

Who Are MYGN's Key Customers?

• Oncologists and cancer patients.
• Women's health specialists and expectant parents.
• Psychiatrists and mental health patients.
• Hospitals and clinics.
• Research institutions.

Myriad Genetics, Inc. Financial Trajectory

Myriad Genetics, Inc. (MYGN) reported $190.7M in revenue for Q2 FY2026, a decline of 4.8% compared to the prior quarter. The company recorded a net loss of $43.2M, with diluted EPS of $-0.46. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, MYGN averaged $-0.30 in diluted EPS.

Company Profile

Myriad Genetics, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO Samraat S. Raha. MYGN has traded publicly since 1995.

How Myriad Genetics, Inc. Is Valued

Myriad Genetics, Inc. carries a market capitalization of $317M, placing it in the small-cap category. Analyst price targets span from $2.00 to $3.60, with a consensus of $2.90. At the current price of $3.36, that implies roughly 14% downside from the consensus target. Relative to its peer group, MYGN's quantitative score of 19/100 is below the peer average of 48/100.

Key Financial Metrics

Return on assets is -59.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -93.2%, the inverse of the P/E and a quick read on earnings relative to price.

Myriad Genetics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.02 places it in the distress zone, a signal of elevated financial risk.

Myriad Genetics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 53.3% below estimates on average.

Over the past six months, Myriad Genetics, Inc. insiders filed 21 SEC Form 4 transactions — 9 sales and 12 purchases. On net that is roughly 655K shares acquired (about $346K) — insiders putting money in tends to read as conviction.

MYGN Financials

MYGN Latest News

MYGN Analyst Consensus

MYGN MoonshotScore

What Investors Ask About Myriad Genetics, Inc. (MYGN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources